Rhythm Biosciences (ASX:RHY) share price jumps 12% on key milestone

The Rhythm Biosciences share price was on fire on Wednesday. Here’s why…
The post Rhythm Biosciences (ASX:RHY) share price jumps 12% on key milestone appeared first on The Motley Fool Australia. –

The Rhythm Biosciences Ltd (ASX: RHY) share price was a very strong performer on Wednesday.

The predictive diagnostics company’s shares ended the day 12% higher at $1.32.

This means the Rhythm Biosciences share price is now up 550% over the last 12 months.

Why did the Rhythm Biosciences share price surge higher today?

Investors were bidding the Rhythm Biosciences share price higher today following the release of a milestone announcement.

According to the release, the company has completed recruitment for its clinical trial (Study 7) for ColoSTAT.

ColoSTAT is a globally marketed, low-cost, simple blood test for the early detection of colorectal cancer aimed at mass-market screening.

The release explains that Rhythm Biosciences has now successfully recruited 815 patients across 11 Australian clinical trial sites. This was deemed to be an adequate number of patients following a detailed consultation with leading industry professionals and the company’s biostatisticians and Clinical Research Organisation (CRO).

Management notes that the recruitment phase is a highly involved and resource intensive component of the clinical trial. Therefore, it feels the completion of this phase represents a significant milestone towards the final completion of the clinical trial study.

What’s next?

The good news for the Rhythm Biosciences share price is that ColoSTAT could be generating revenue in the not so distant future.

The company will now commence testing the collected blood samples, finalise and lock the patient database, and other routine associated works. It will also progress the next stages in finalising the trial, before completing the final clinical study report.

If all goes to plan, the clinical trial is targeted for completion in the first half of calendar year 2022. After which, it is hoping for approval to market ColoSTAT within Australia later that year.

European trials are ongoing as well, with a filing expected to be made before the end of the year.

Management commentary

Rhythm’s CEO, Glenn Gilbert, said: “With the recruitment target now met for the ColoSTAT clinical trial, the Company remains fully focused on working with our partners to progress through the remaining phases for trial completion.”

“In the context of market conditions made extremely difficult by COVID-19, I am proud of the achievement by the entire Rhythm team, our trial sites, CRO, operations and laboratory partners. This milestone should not be understated, considering the recruitment phase is typically the most resource, logistically challenging and cost intensive component of completing a clinical trial,” he added.

Management estimates that ColoSTAT has a $6.5 billion market opportunity across the US, European, and Australian markets.

The post Rhythm Biosciences (ASX:RHY) share price jumps 12% on key milestone appeared first on The Motley Fool Australia.

Should you invest $1,000 in Rhythm right now?

Before you consider Rhythm, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Rhythm wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why the Rhythm Biosciences (ASX:RHY) share price is jumping 8% today
Why the Rhythm Biosciences (ASX:RHY) share price is flying higher today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!